MA51570A - Polythérapies pour le traitement du carcinome hépatocellulaire - Google Patents

Polythérapies pour le traitement du carcinome hépatocellulaire

Info

Publication number
MA51570A
MA51570A MA051570A MA51570A MA51570A MA 51570 A MA51570 A MA 51570A MA 051570 A MA051570 A MA 051570A MA 51570 A MA51570 A MA 51570A MA 51570 A MA51570 A MA 51570A
Authority
MA
Morocco
Prior art keywords
polytherapies
treatment
hepatocellular carcinoma
hepatocellular
carcinoma
Prior art date
Application number
MA051570A
Other languages
English (en)
Inventor
Anand Selvaraj
Peter Smith
Original Assignee
Eisai R&D Man Co Ltd
Anand Selvaraj
Peter Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Anand Selvaraj, Peter Smith filed Critical Eisai R&D Man Co Ltd
Publication of MA51570A publication Critical patent/MA51570A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA051570A 2018-01-10 2019-01-09 Polythérapies pour le traitement du carcinome hépatocellulaire MA51570A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862615848P 2018-01-10 2018-01-10

Publications (1)

Publication Number Publication Date
MA51570A true MA51570A (fr) 2020-11-18

Family

ID=65411938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051570A MA51570A (fr) 2018-01-10 2019-01-09 Polythérapies pour le traitement du carcinome hépatocellulaire

Country Status (13)

Country Link
US (1) US11833119B2 (fr)
EP (2) EP3737377B1 (fr)
JP (2) JP7352569B2 (fr)
KR (2) KR102811519B1 (fr)
CN (1) CN111787922A (fr)
AU (1) AU2019206480A1 (fr)
BR (1) BR112020014112A2 (fr)
CA (1) CA3088292A1 (fr)
IL (1) IL275981A (fr)
MA (1) MA51570A (fr)
MX (1) MX2020007375A (fr)
SG (1) SG11202006617RA (fr)
WO (1) WO2019139977A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021230886A1 (fr) * 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. Procédé de traitement du cancer avec une forme posologique orale d'un inhibiteur de fgfr4
EP4534087A1 (fr) 2022-05-30 2025-04-09 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Association pharmaceutique et composition pharmaceutique pour le traitement du cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
CN100569753C (zh) 2003-12-25 2009-12-16 卫材R&D管理有限公司 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的甲磺酸盐的结晶(c)及其制备方法
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
KR20140117457A (ko) * 2012-01-31 2014-10-07 노파르티스 아게 Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
ES2705698T3 (es) * 2013-06-26 2019-03-26 Eisai R&D Man Co Ltd Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib
LT3057943T (lt) * 2013-10-18 2018-11-12 Eisai R&D Management Co., Ltd. Pirimidino fgfr4 slopikliai
KR102479696B1 (ko) * 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
US20160089365A1 (en) * 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound
WO2016168331A1 (fr) 2015-04-14 2016-10-20 Eisai R&D Management Co., Ltd. Composé inhibiteur de fgfr4 cristallin et utilisations de celui-ci
CN107304188A (zh) * 2016-04-20 2017-10-31 成都融科博海科技有限公司 一种氘代激酶选择性抑制剂及其应用
JP7372740B2 (ja) * 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ

Also Published As

Publication number Publication date
BR112020014112A2 (pt) 2020-12-01
US20200360371A1 (en) 2020-11-19
KR20200121302A (ko) 2020-10-23
WO2019139977A1 (fr) 2019-07-18
AU2019206480A1 (en) 2020-08-27
EP4667005A3 (fr) 2026-02-18
JP7352569B2 (ja) 2023-09-28
US11833119B2 (en) 2023-12-05
EP4667005A2 (fr) 2025-12-24
IL275981A (en) 2020-08-31
RU2020126673A (ru) 2022-02-10
SG11202006617RA (en) 2020-08-28
KR20250073570A (ko) 2025-05-27
MX2020007375A (es) 2020-11-09
JP2023175825A (ja) 2023-12-12
EP3737377B1 (fr) 2025-10-08
EP3737377A1 (fr) 2020-11-18
JP7665700B2 (ja) 2025-04-21
CN111787922A (zh) 2020-10-16
KR102811519B1 (ko) 2025-05-22
CA3088292A1 (fr) 2019-07-18
RU2020126673A3 (fr) 2022-04-19
JP2021512140A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3773221A4 (fr) Traitement pour l'hydrocéphalie